Literature DB >> 18653740

Multiple sclerosis: reduced proportion of circulating plasmacytoid dendritic cells expressing BDCA-2 and BDCA-4 and reduced production of IL-6 and IL-10 in response to herpes simplex virus type 1.

A Sanna1, Y M Huang, G Arru, M L Fois, H Link, G Rosati, S Sotgiu.   

Abstract

OBJECTIVE: We hypothesized that autoaggressive immune responses observed in multiple sclerosis (MS) could be associated with an imbalance in proportion of immune cell subsets and in cytokine production in response to infection, including viruses.
METHODS: We collected blood mononuclear cells (MNC) from 23 patients with MS and 23 sex- and age-matched healthy controls (HC) from the island of Sardinia, Italy, where the prevalence of MS is extraordinarily high. Using flow cytometry, we studied MNC for expression of blood dendritic cell antigens (BDCA)-2 and BDCA-4 surface markers reflecting the proportion of plasmacytoid dendritic cells (pDC) that produce type I interferons (IFNs) after virus challenge and promote Th2/anti-inflammtory cytokine production. In parallel, pro-inflammatory (interleukin [IL]-2, IL-12, IFN-gamma), anti-inflammatory (IL-4, IL-10), and immuno-regulatory/pleiotropic cytokines (type I IFNs including IFN-alpha and beta, IL-6) were measured before and after an in vitro exposure to herpes simplex virus type 1 (HSV-1).
RESULTS: The subset of lineage negative (lin(-)), BDCA-2(+) cells was lower in patients with MS compared with HC (0.08 + or - 0.02% vs 0.24 + or - 0.02%; P < 0.001). A similar pattern was observed for lin(-)BDCA-4(+) cells (0.08 + or - 0.02% vs 0.17% + or - 0.03; P < 0.01). Spontaneous productions of IL-6 (45 + or - 10 pg/mL vs 140 + or - 26 pg/mL; P < 0.01) and IL-10 (17 + or - 0.4 pg/mL vs 21 + or - 1 pg/mL; P < 0.05) by MNC were lower in patients with MS compared with HC. Spontaneous production of IL-6 (6.5 + or - 0.15 pg/mL vs 21 + or - 5 pg/mL; P < 0.01 and IL-10 (11 + or - 1 pg/mL vs 14 + or - 3 pg/mL; P < 0.05) by pDC was also lower in patients with MS compared with HC. Exposure of MNC to HSV-1 showed, in both patients with MS and HC, increased production of IFN-alpha, IL-6, and IL-10 but decreased production of IL-4. In response to HSV-1 exposure, productions of IL-6 (165 +or - 28 pg/mL vs 325 + or - 35 pg/mL; P < 0.01) and IL-10 (27 +or - 3 vs 33 + or - 3 P < 0.05) by MNC as well as by pDC (IL-6: 28 + or - 7 vs 39 + or - 12 P < 0.05; IL-10: 14 + or - 1 vs 16 + or - 3 P < 0.05) were lower in patients with MS compared with HC.
CONCLUSION: The results implicate a new evidence for altered immune cells and reduced immune responses in response to viral challenge in MS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18653740     DOI: 10.1177/1352458508094401

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  6 in total

Review 1.  Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.

Authors:  Sara J Ireland; Nancy L Monson; Laurie S Davis
Journal:  Cytokine       Date:  2015-03-17       Impact factor: 3.861

2.  Subacute herpes simplex virus type 1 encephalitis as an initial presentation of chronic lymphocytic leukemia and multiple sclerosis: a case report.

Authors:  Rashi L Singhal; Lourdes C Corman
Journal:  J Med Case Rep       Date:  2011-02-11

3.  Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis.

Authors:  Clara de Andrés; Roseta Teijeiro; Bárbara Alonso; Francisco Sánchez-Madrid; M Luisa Martínez; Juan Guzmán de Villoria; Eduardo Fernández-Cruz; Silvia Sánchez-Ramón
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

4.  Mendelian Randomization Analysis Suggests No Associations of Herpes Simplex Virus Infections With Multiple Sclerosis.

Authors:  Wan Zhang; Pengfei Wu; Rui Yin; Meichen Sun; Rongsen Zhang; Xiaoyao Liao; Yuhong Lin; Hui Lu
Journal:  Front Neurosci       Date:  2022-03-01       Impact factor: 4.677

Review 5.  The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.

Authors:  Stanley L Cohan; Ralph H B Benedict; Bruce A C Cree; John DeLuca; Le H Hua; Jerold Chun
Journal:  CNS Drugs       Date:  2022-06-20       Impact factor: 6.497

Review 6.  Innate immune responses in the CNS: role of toll-like receptors, mechanisms, and therapeutic opportunities in multiple sclerosis.

Authors:  Giulio Podda; Mukanthu Nyirenda; James Crooks; Bruno Gran
Journal:  J Neuroimmune Pharmacol       Date:  2013-06-28       Impact factor: 7.285

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.